Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects

AIDS Research and Human Retroviruses

Volumn 26, Issue 10, 2010, Pages 1047-1049

  Papasavvas, Emmanouil ^a   Chehimi, Jihed ^a   Azzoni, Livio ^a   Pistilli, Maxwell ^a   Thiel, Brian ^a   MacKiewicz, Agnieszka ^a   Creer, Shenoa ^a   Mounzer, Karam ^b,c   Kostman, Jay R ^b,c   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b Philadelphia Field Initiating Group for HIV 1 Trials   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; CHRONIC DISEASE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LETTER; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

CD4 LYMPHOCYTE COUNT; DENDRITIC CELLS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; VIRUS REPLICATION;

EID: 77958198974     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0020     Document Type: Letter

References (15)

1. Chehimi J, Campbell DE, Azzoni L, et al.: Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002;168:4796-4801.
2. Donaghy H, Pozniak A, Gazzard B, et al.: Loss of blood CD11c (+) myeloid and CD11c (-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001;98:2574-2576.
3. Azzoni L, Papasavvas E, Chehimi J, et al.: Sustained impairment of IFNgamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: Evidence for a defective reconstitution of innate immunity. J Immunol 2002;168:5764-5770.
4. Knight SC, Macatonia SE, and Patterson S: HIV I infection of dendritic cells. Int Rev Immunol 1990;6:163-175.
5. Azzoni L, Chehimi J, Zhou L, et al.: Early and delayed benefits of HIV-1 suppression: Timeline of recovery of innate immunity effector cells. AIDS 2007;21:293-305.
6. Azzoni L, Papasavvas E, and Montaner LJ: Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparing. Curr HIV Res 2003;1:329-342.
7. Papasavvas E, Ortiz GM, Gross R, et al.: Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000;182:766-775.
8. Chehimi J, Azzoni L, Farabaugh M, et al.: Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol 2007;179:2642-2650.
9. Dybul M, Chun TW, Yoder C, et al.: Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001;98:15161-15166.
10. Dybul M, Nies-Kraske E, Daucher M, et al.: Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003;188:388-396.
11. Garcia F, Plana M, Ortiz GM, et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15: F29-40.
12. Ortiz GM, Wellons M, Brancato J, et al.: Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 2001;98:13288-13293.
13. Oxenius A, Price DA, Gunthard HF, et al.: Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002;99:13747-13752.
14. Papasavvas E, Kostman JR, Mounzer K, et al.: Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004;1: e64.
15. Papasavvas E, Pistilli M, Reynolds G, et al.: Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 2009;23:369-375.